150 related articles for article (PubMed ID: 32748747)
21. Inhibiting BDNF/TrkB.T1 receptor improves resiniferatoxin-induced postherpetic neuralgia through decreasing ASIC3 signaling in dorsal root ganglia.
Wei X; Wang L; Hua J; Jin XH; Ji F; Peng K; Zhou B; Yang J; Meng XW
J Neuroinflammation; 2021 Apr; 18(1):96. PubMed ID: 33874962
[TBL] [Abstract][Full Text] [Related]
22. Brain-derived neurotrophic factor activation of TrkB protects neuroblastoma cells from chemotherapy-induced apoptosis via phosphatidylinositol 3'-kinase pathway.
Jaboin J; Kim CJ; Kaplan DR; Thiele CJ
Cancer Res; 2002 Nov; 62(22):6756-63. PubMed ID: 12438277
[TBL] [Abstract][Full Text] [Related]
23. Expression and pharmacological inhibition of TrkB and EGFR in glioblastoma.
Pinheiro KV; Thomaz A; Souza BK; Metcalfe VA; Freire NH; Brunetto AT; de Farias CB; Jaeger M; Bambini V; Smith CGS; Shaw L; Roesler R
Mol Biol Rep; 2020 Sep; 47(9):6817-6828. PubMed ID: 32862352
[TBL] [Abstract][Full Text] [Related]
24. Targeting TRK family proteins in cancer.
Khotskaya YB; Holla VR; Farago AF; Mills Shaw KR; Meric-Bernstam F; Hong DS
Pharmacol Ther; 2017 May; 173():58-66. PubMed ID: 28174090
[TBL] [Abstract][Full Text] [Related]
25. MiR-1-3p inhibits cell proliferation and invasion by regulating BDNF-TrkB signaling pathway in bladder cancer.
Gao L; Yan P; Guo FF; Liu HJ; Zhao ZF
Neoplasma; 2018; 65(1):89-96. PubMed ID: 29322793
[TBL] [Abstract][Full Text] [Related]
26. Tropomyosin-related kinase B mediated signaling contributes to the induction of malignant phenotype of gallbladder cancer.
Kawamoto M; Onishi H; Ozono K; Yamasaki A; Imaizumi A; Kamakura S; Nakano K; Oda Y; Sumimoto H; Nakamura M
Oncotarget; 2017 May; 8(22):36211-36224. PubMed ID: 28423707
[TBL] [Abstract][Full Text] [Related]
27. Estradiol induces BDNF/TrkB signaling in triple-negative breast cancer to promote brain metastases.
Contreras-Zárate MJ; Day NL; Ormond DR; Borges VF; Tobet S; Gril B; Steeg PS; Cittelly DM
Oncogene; 2019 Jun; 38(24):4685-4699. PubMed ID: 30796353
[TBL] [Abstract][Full Text] [Related]
28. Uncovering the role of brain-derived neurotrophic factor/tyrosine kinase receptor B signaling in head and neck malignancies.
de Moraes JK; Wagner VP; Fonseca FP; Vargas PA; de Farias CB; Roesler R; Martins MD
J Oral Pathol Med; 2018 Mar; 47(3):221-227. PubMed ID: 28650560
[TBL] [Abstract][Full Text] [Related]
29. Brain-derived neurotrophic factor promotes proliferation and progesterone synthesis in bovine granulosa cells.
Chen S; Wang F; Liu Z; Zhao Y; Jiang Y; Chen L; Li C; Zhou X
J Cell Physiol; 2019 Jun; 234(6):8776-8787. PubMed ID: 30456817
[TBL] [Abstract][Full Text] [Related]
30. TrkB/BDNF signaling pathway is a potential therapeutic target for pulmonary large cell neuroendocrine carcinoma.
Odate S; Nakamura K; Onishi H; Kojima M; Uchiyama A; Nakano K; Kato M; Tanaka M; Katano M
Lung Cancer; 2013 Mar; 79(3):205-14. PubMed ID: 23312550
[TBL] [Abstract][Full Text] [Related]
31. Phrenic long-term facilitation after acute intermittent hypoxia requires spinal ERK activation but not TrkB synthesis.
Hoffman MS; Nichols NL; Macfarlane PM; Mitchell GS
J Appl Physiol (1985); 2012 Oct; 113(8):1184-93. PubMed ID: 22961271
[TBL] [Abstract][Full Text] [Related]
32. GZD2202, a novel TrkB inhibitor, suppresses BDNF-mediated proliferation and metastasis in neuroblastoma models.
Zou J; Zhang Z; Xu F; Cui S; Qi C; Luo J; Wang Z; Lu X; Tu Z; Ren X; Song L; Ding K
J Drug Target; 2019 Apr; 27(4):442-450. PubMed ID: 30301369
[TBL] [Abstract][Full Text] [Related]
33. Rab8A promotes breast cancer progression by increasing surface expression of Tropomyosin-related kinase B.
Liu Y; Zhang Z; Gao X; Ma Q; Yu Z; Huang S
Cancer Lett; 2022 Jun; 535():215629. PubMed ID: 35278612
[TBL] [Abstract][Full Text] [Related]
34. Activation of BDNF/TrkB pathway promotes prostate cancer progression via induction of epithelial-mesenchymal transition and anoikis resistance.
Li T; Yu Y; Song Y; Li X; Lan D; Zhang P; Xiao Y; Xing Y
FASEB J; 2020 Jul; 34(7):9087-9101. PubMed ID: 32390303
[TBL] [Abstract][Full Text] [Related]
35. Tropomyosin receptor kinase inhibitors: an updated patent review for 2016-2019.
Bailey JJ; Jaworski C; Tung D; Wängler C; Wängler B; Schirrmacher R
Expert Opin Ther Pat; 2020 May; 30(5):325-339. PubMed ID: 32129124
[No Abstract] [Full Text] [Related]
36. TRK Inhibitors: Clinical Development of Larotrectinib.
Bhangoo MS; Sigal D
Curr Oncol Rep; 2019 Feb; 21(2):14. PubMed ID: 30715603
[TBL] [Abstract][Full Text] [Related]
37. Targeting BDNF/TrkB pathways for preventing or suppressing epilepsy.
Lin TW; Harward SC; Huang YZ; McNamara JO
Neuropharmacology; 2020 May; 167():107734. PubMed ID: 31377199
[TBL] [Abstract][Full Text] [Related]
38. Entrectinib in patients with advanced or metastatic NTRK fusion-positive solid tumours: integrated analysis of three phase 1-2 trials.
Doebele RC; Drilon A; Paz-Ares L; Siena S; Shaw AT; Farago AF; Blakely CM; Seto T; Cho BC; Tosi D; Besse B; Chawla SP; Bazhenova L; Krauss JC; Chae YK; Barve M; Garrido-Laguna I; Liu SV; Conkling P; John T; Fakih M; Sigal D; Loong HH; Buchschacher GL; Garrido P; Nieva J; Steuer C; Overbeck TR; Bowles DW; Fox E; Riehl T; Chow-Maneval E; Simmons B; Cui N; Johnson A; Eng S; Wilson TR; Demetri GD;
Lancet Oncol; 2020 Feb; 21(2):271-282. PubMed ID: 31838007
[TBL] [Abstract][Full Text] [Related]
39. BDNF mimetic compound LM22A-4 regulates cementoblast differentiation via the TrkB-ERK/Akt signaling cascade.
Kajiya M; Takeshita K; Kittaka M; Matsuda S; Ouhara K; Takeda K; Takata T; Kitagawa M; Fujita T; Shiba H; Kurihara H
Int Immunopharmacol; 2014 Apr; 19(2):245-52. PubMed ID: 24530412
[TBL] [Abstract][Full Text] [Related]
40. BDNF/TrkB signaling protects HT-29 human colon cancer cells from EGFR inhibition.
de Farias CB; Heinen TE; dos Santos RP; Abujamra AL; Schwartsmann G; Roesler R
Biochem Biophys Res Commun; 2012 Aug; 425(2):328-32. PubMed ID: 22842573
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
